Deals aimed at lowering drug prices in the United States could cause higher prices for new medicines in Switzerland, according to the head of Swiss drugmaker Roche.
The warning comes after Washington announced agreements with major pharmaceutical companies to cut prices for medicines sold to low-income Americans through the Medicaid program.
